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Abstract
Background: At the present, a shift from drug therapy, especially herbal therapy, to dietary supplementation is a
trend in the management of dyslipidemia and related diseases. Therefore, the optimal utilization of herbal resource
is important for a sustainable development of herbal medicine. Here, we compared the effects of dietary
supplementation with Chinese medicine Schisandrae Chinensis Fructus seed (FSC-S) and the post-ethanol
extraction residue of FSC-S (FSC-SpEt) on normal diet-fed (normal) and experimental hypercholesterolemic (HCL)
mice.
Methods: Male ICR mice (n = 10 in each group), weighing 17–21 g, were fed with normal diet (ND) or high
cholesterol/bile salt (1/0.3 %, w/w) diet (HCBD) with or without supplemented with FSC-S, FSC-SpEt), or lipid-lowering
agent fenofibrate (FF). Ten days later, serum/hepatic lipid and glucose (GLU) levels, body weight, organ/epididymal fat
masses, and food/water intake were measured. Lipid level measurements included those of total cholesterol (TC),
triglyceride (TG), high density lipoprotein (HDL), low density lipoprotein (LDL), HDL/LDL ratio, LDL/HDL ratio, and
non-HDL (N-HDL).
Results: Supplementation with FSC-S and FSC-SpEt increased serum TC (by 64 and 25 %, respectively) and LDL (by 60
and 27 %, respectively) in normal mice. FSC-S supplementation elevated serum TC, TG, HDL, LDL, and LDL/HDL ratio
(up to 64, 118, 77, 197, and 51 %, respectively) in HCL mice. FSC-SpEt supplementation reduced serum TG (by 15 %)
and LDL/HDL ratio (by 18 %), as well as increased serum HDL (by 22 %) and HDL/LDL ratio (by 21 %) in HCBD-fed
mice. FSC-S decreased hepatic TC (by 19 %) contents and increased hepatic TG contents by 14 % in normal mice.
FSC-S reduced hepatic GLU level in both normal and HCL mice by 24 and 22 %, respectively. Hepatic TC and TG
contents were lowered in FSC-SpEt-supplemented normal mice by 16 and 20 %, respectively. The body/fatty masse
and food intake were lowered, but the feed efficiency index (FEI), weight gain per unit of food ingested, was increased
in FSC-S-supplemented normal and HCL mice. FF supplements reduced serum/hepatic lipids, hepatic GLU contents,
and epididymal fat mass, but it induced hepatomegaly and high serum alanine aminotransferase (ALT) activity in
normal and/or HCL mice.
Conclusion: The ensemble of results indicated that while FSC-SpEt supplementation is beneficial for the treatment of
hyperlipidemia/fatty liver, FSC-S is potentially useful for the management of overweight/obesity.
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Background
With dietary and lifestyle changes such as increases in
high caloric food intake and sedentary lifestyle, there has
been an appreciable rise in the prevalence of cardiovas-
cular diseases (CVD) and obesity/overweight in develop-
ing countries [1, 2]. Among many pathogenetic factors,
hyperlipidemia, especially hypertriglyceridemia, is con-
sidered as a significant risk factor for CVD, particularly
the coronary heart disease [3, 4]. Therefore, reducing
blood lipids and body mass is an important strategy for
preventing the occurrence and progression of CVD. At
present, drugs used for the treatment of hyperlipidemia
include HMG CoA reductase inhibitors, fibrates, chol-
esterol absorption inhibitors, nicotinic acid group and
bile acid sequestrants [5]. In the market, there are more
than 10 prescription anti-obesity drugs such as Reduc-
til, Xenical, Didrex, Tenuate, Belviq, Bontril, Adipex,
Orlistat, and Qsymia, etc [6–8]. While most currently
used lipid-lowering and weight-loss chemicals are either
expensive or having potential side effects, recent re-
search has been focused on exploring alternative nat-
ural medicines for the prevention and/or treatment of
hyperlipidemia and/or obesity [9, 10]. However, a num-
ber of medicinal plants are facing the threat of extinc-
tion due to overexploitation [11, 12]. The situation can
partly be attributed to the waste of natural herbal re-
sources in pharmaceutical industry.
Schisandrae Chinensis Fructus (FSC, Wuweizi in
Chinese), the fruit of Schisandra chinensis (Turcz.) Baill,
is a commonly prescribed herb in traditional Chinese
medicine, particularly in a number of tonic formulae.
FSC has previously been reported to have a wide
spectrum of biological effects, including protecting against
chemically and virally induced hepatic injury [13, 14],
improving insulin sensitivity [15], protecting against
oxidative damage [16], producing sedative–hypnotic
activity and anti-inflammatory effects [17, 18]. Our
previous works have demonstrated that FSC extract
and FSC-related compounds significantly altered lipid
metabolism in mice [19–23]. In the present study, we
endeavored to evaluate the effects of dietary supple-
mentation with FSC seed (FSC-S) and the post-ethanol
extraction residue of FSC-S (FSC-SpEt) on serum and
hepatic lipid/glucose (GLU) contents in both normal
diet-fed (ND) and high cholesterol/bile salt diet-fed
(HCBD) mice, an animal model of hypercholesterol-
emia (HCL). Fenofibrate (FF), the most commonly pre-
scribed lipid-lowering agent in Western medicine [24],
was used as a positive control for comparison. The lipid
profile measurements in the serum and liver samples
included total cholesterol (TC), triglyceride (TG), and
non-HDL (N-HDL), as well as high density lipoprotein
(HDL), low density lipoprotein (LDL), HDL/LDL ratio,
and LDL/HDL ratio.
Results
Effects of FSC-S and FSC-SpEt supplementation on serum
lipid profiles and GLU
As shown in Table 1, feeding mice with FSC-S supple-
mented ND produced noticeable increases in serum TC
(64 %), TG (155 %), HDL (68 %), and LDL (60 %) levels,
but a decrease in serum GLU level by 32 %, when com-
pared with the control group (i.e., un-supplemented
ND). FSC-SpEt supplementation increased serum TC
(by 25 %), LDL (27 %) and N-HDL (60 %) levels, as well
as LDL/HDL ratio (15 %). However, it decreased the
HDL/LDL ratio by 15 %. Daily supplementation with FF
decreased serum TG level by 44 % in normal mice.
HCBD-fed mice increased serum TC, LDL, and N-
HDL levels (33, 317, and 102 %, respectively) as well as
the LDL/HDL ratio (317 %), while serum TG level and
HDL/LDL ratio were decreased by 23 and 76 %, respect-
ively, when compared with those of normal mice. FSC-S
supplementation significantly increased serum TC
(64 %), TG (118 %), HDL (77 %) and LDL (107 %) levels
in a dose-dependent manner in HCBD-fed mice. FSC-
SpEt treatment increased both serum HDL (22 %) and
HDL/LDL ratio (21 %), but decreased serum TG (15 %)
and N-HDL (17 %) levels as well as LDL/HDL ratio
(18 %) in HCL mice. FF treatment reduced serum TC
(30 %), TG (21 %), HDL (21 %), LDL (55 %), and N-
HDL (39 %) levels, but increased HDL/LDL ratio (85 %)
in HCL mice (Table 1).
Effects of FSC-S and FSC-SpEt supplementation on hepatic
lipids and GLU
As shown in Table 2, the supplementation with FSC-S
and FSC-SpEt decreased hepatic TC content by 19 %
and 16 %, respectively, in normal mice. Supplementation
with FSC-S increased hepatic TG (14 %) contents and de-
creased hepatic GLU (24 %) contents, whereas FSC-SpEt
supplementation decreased hepatic TG contents (20 %).
ND supplemented with FF reduced hepatic TC, TG, and
GLU contents by 59, 50 and 28 %, respectively, when
compared with the un-supplemented normal mice. Feed-
ing mice with HCBD for 10 days markedly increased hep-
atic TC and TG contents by 57 and 63 %, respectively.
When compared with un-supplemented HCL mice, the
dietary consumption of FSC-S increased hepatic TG con-
tent (up to 20 %), and reduced hepatic GLU (up to 22 %)
in a dose-dependent manner. Daily supplementation with
FF lowered hepatic TC, TG and GLU contents by 64, 43,
and 39 %, respectively (Table 2).
Effects of FSC-S and FSC-SpEt supplementation on hepatic
size and liver function
In normal mice, supplementations with FSC-S, FSC-
SpEt, and FF caused an elevation in hepatic index by 56,
10, and 67 %, respectively, when compared with the un-
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supplemented control. Mice fed with HCBD for 10 days
produced an increase in liver size by 16 % and serum
alanine aminotransferase (ALT) activity by 22 %, when
compared with the ND-fed mice. FSC-S, but not FSC-
SpEt supplementation increased hepatic weight and
index (up to 36 and 58 %, respectively) and serum ALT
activity (approximately 33 %) in a dose-dependent man-
ner. FF supplementation elevated hepatic weight, hepatic
index, and serum ALT activity by 67, 71, and 78 %, re-
spectively, in HCL mice (Table 3).
Effects of FSC-S and FSC-SpEt supplementation on organ/
tissue weight/indices
Supplementation with both FSC-S and FF significantly
decreased the epididymis fat weight and index in both
normal and HCL mice. FSC-S supplementation also re-
duced kidney and spleen mass in both normal and HCL
mice. For the normal mice, FSC-S did not change the
testis weight but increased testis index 1 or index 2 by
32 and 39 %, respectively. However, FSC-SpEt supple-
mentation did not alter these organ and epididymis fat
weight and indices (Table 4).
Effects of FSC-S and FSC-SpEt supplementation on stomach
weight/indices, residual gastric contents and fecal TC
contents
Feeding mice with ND-supplemented FSC-S significantly
reduced stomach weight by 26 %, but it increased
Table 1 Effects of FSC-S and FSC-SpEt supplementation on serum lipid profiles and GLU in normal and experimental hypercholester-
olemic (HCL) mice
Groups Dose TC TG HDL LDL HDL/LDL LDL/HDL N-HDL GLU
(%, w/w) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L) (mmol/L)
Normal mice
ND - 3.58 ± 0.17 1.42 ± 0.21 2.41 ± 0.05 0.30 ± 0.01 8.06 ± 0.32 0.13 ± 0.01 1.17 ± 0.15 10.29 ± 0.50
ND/FSC-S 9 5.87 ± 0.34** 3.62 ± 0.31** 4.06 ± 0.11** 0.48 ± 0.02** 8.74 ± 0.50 0.12 ± 0.01 1.80 ± 0.37 7.03 ± 0.48**
ND/FSC-SpEt 9 4.46 ± 0.16** 1.22 ± 0.09 2.58 ± 0.09 0.38 ± 0.01** 6.86 ± 0.22** 0.15 ± 0.01** 1.87 ± 0.14** 11.47 ± 0.29
ND/FF 0.05 3.66 ± 0.30 0.79 ± 0.04* 2.36 ± 0.07 0.33 ± 0.02 7.40 ± 0.45 0.14 ± 0.01 1.29 ± 0.28 10.96 ± 0.41
HCL mice
ND - 4.31 ± 0.15 1.29 ± 0.04 2.96 ± 0.15 0.36 ± 0.03 8.67 ± 0.54 0.12 ± 0.01 1.35 ± 0.10 8.14 ± 0.36
HCBD - 5.74 ± 0.19** 0.99 ± 0.04** 3.00 ± 0.08 1.50 ± 0.07** 2.05 ± 0.13** 0.50 ± 0.02** 2.73 ± 0.15** 8.00 ± 0.19
HCBD/FSC-S 3 6.98 ± 0.32## 1.23 ± 0.12 3.72 ± 0.14## 2.22 ± 0.08## 1.68 ± 0.05# 0.60 ± 0.02## 3.26 ± 0.21 7.78 ± 0.28
9 9.41 ± 0.55## 2.16 ± 0.29## 5.30 ± 0.24## 3.11 ± 0.23## 1.76 ± 0.10 0.59 ± 0.04 4.11 ± 0.50# 7.01 ± 0.48
HCBD/FSC-SpEt 3 5.96 ± 0.27 0.73 ± 0.03## 3.25 ± 0.10 1.51 ± 0.09 2.34 ± 0.18 0.47 ± 0.03 2.71 ± 0.24 8.33 ± 0.55
9 5.91 ± 0.16 0.84 ± 0.05# 3.65 ± 0.18## 1.50 ± 0.09 2.49 ± 0.12# 0.41 ± 0.02# 2.26 ± 0.16# 8.43 ± 0.26
HCBD/FF 0.05 4.03 ± 0.16## 0.78 ± 0.04## 2.37 ± 0.08## 0.67 ± 0.06## 3.80 ± 0.39## 0.28 ± 0.02## 1.66 ± 0.15## 7.69 ± 0.30
Mice were fed with normal diet (ND) or high cholesterol/bile salt (1/0.3 %, w/w) diet (HCBD) to establish a model of mouse hypercholesterolemia (HCL). Fructus
Schisandrae Chinensis seed (FSC-S) and post-ethanol extraction residue of FSC-S (FSC-SpEt) were smashed to pass through the 60 mesh sieve and mixed with
either ND or HCBD at the indicated doses, which were estimated on the basis of crude herbal material. Fenofibrate (FF) was adopted as a positive control for
comparison. Ten days after dietary supplementation, serum total cholesterol (TC), triglyceride (TG), high-density lipoprotein (HDL), low-density lipoprotein (LDL),
non-HDL (N-HDL), and glucose (GLU) levels, as well as HDL/LDL and LDL/HDL ratio were measured. Values given are the means ± SEM, with n = 10. *P < 0.05,
**P < 0.01 vs ND; #P < 0.05, ##P < 0.01 vs HCBD. Statistical significant differences were determined using a one-way ANOVA followed by Dunnett’s multiple
comparisons test or post-hoc analysis
Table 2 Effects of diet supplementation with FSC-S and FSC-SpEt
on hepatic lipids and GLU in normal and experimental
hypercholesterolemic (HCL) mice
Groups Dose TC TG GLU
(%, w/w) (μmol/g) (μmol/g) (μmol/g)
Normal mice
ND – 3.94 ± 0.11 7.14 ± 0.15 132.98 ± 3.13
ND/FSC-S 9 3.21 ± 0.09** 8.14 ± 0.31** 100.86 ± 2.80**
ND/FSC-SpEt 9 3.31 ± 0.13** 5.73 ± 0.18** 138.95 ± 3.83
ND/FF 0.05 1.61 ± 0.06** 3.54 ± 0.25** 95.37 ± 3.67**
HCL mice
ND – 7.35 ± 0.08 6.82 ± 0.11 106.81 ± 3.83
HCBD – 11.52 ± 0.55** 11.12 ± 0.82** 107.67 ± 2.88
HCBD/FSC-S 3 12.45 ± 0.39 13.05 ± 0.58 97.57 ± 2.35#
9 11.90 ± 0.05 13.35 ± 0.48# 84.48 ± 1.65##
HCBD/FSC-SpEt 3 11.59 ± 0.51 10.13 ± 0.43 102.84 ± 1.67
9 10.70 ± 0.47 9.70 ± 0.55 104.73 ± 1.67
HCBD/FF 0.05 7.02 ± 0.22## 6.34 ± 0.15## 65.67 ± 2.14##
Experimental details were described in Table 1. Mice were fed with ND and
HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Ten days after
supplementation, hepatic TC, TG and GLU contents were determined. Values
given are the means ± SEM, with n = 10. *P < 0.05, **P < 0.01 vs ND; #P < 0.05,
##P < 0.01 vs HCBD. Statistical significant differences were determined using a
one-way ANOVA followed by Dunnett’s multiple comparisons test or
post-hoc analysis
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residual gastric content and both index 1 and 2 by 33, 87,
or 94 %, respectively. Supplementation with FSC-SpEt
showed no effect on stomach weight and residual gastric
content or indices, but it decreased fecal TC level by 18 %.
FF supplementation reduced stomach weight and index 1
by 18 and 14 %, respectively. In HCL mice, fecal TC level
was significantly increased by 342 %. FF supplementation
increased fecal TC level by 20 % and stomach index 2 by
12 % in HCBD mice, when compared with un-
supplemented HCBD mice. FSC-S treatment increased
stomach index 2 (13 %) and residual gastric content index
1 (41 %) and 2 (48 %) in HCL mice. FSC-SpEt supplemen-
tation decreased residual gastric content and the index
(up to 32 %) in HCL mice (Table 5).
Effects of FSC-S and FSC-SpEt supplementation on body
weight
FSC-S supplement suppressed the increase in body
weight (approximately 28 % in normal mice and 13 % in
HCL mice), when compared with the corresponding
normal and HCL mice without FSC-S supplementation.
FSC-S and FF reduced the values of body weight minus
liver weight by 31 and 7 % in normal mice and 17 and
7 % in HCL mice, respectively. FSC-SpEt did not alter
the body weight gain in both mice (Table 6).
Effects of FSC-S and FSC-SpEt supplementation on food,
water, and drug intake
As shown in Table 7, the ratio of food and water intake
to body weight (RFBW and RWBW, respectively) and
feed efficiency index (FEI) and water efficiency index
(WEI) values showed no detectable differences between
normal and HCL mice. While FSC-S supplementation at
the dose of 9 % reduced RFBW by 18 % in both normal
and HCL mice, it elevated FEI and WEI by 133 and
95 % in normal mice and 33 and 41 % in HCL mice, re-
spectively. However, FSC-SpEt and FF supplementations
did not alter the daily food/water intake in normal and
HCL mice. Daily intake of FSC-S/FSC-SpEt was esti-
mated to be 5.13/5.44 g/kg (based on crude herb equiva-
lent) and 12.73-12.79/16.76-17.93 g/kg at 3 % and 9 %
supplementation, respectively. FF was estimated to be
0.08 and 0.1 g/kg/day in ND-fed and HCL mice,
respectively.
Discussion
It is well known that dietary intake is causally related to
hyperlipidemia, including hypercholesterolemia, hypertri-
glyceridemia and their combination in experimental ani-
mals and humans [25–27]. In the present study, feeding
mice with HCBD for 10 days caused significant increases
in serum TC and LDL levels, but serum TG level was sig-
nificantly decreased. This is consistent with observations
in our previous study [20, 21]. However, it has been shown
that elevations in serum TC and TG occur in rabbits fed a
diet supplemented with 1 % cholesterol for 60 days [28].
The degree of cholesterol-induced hypertriglyceridemia
may vary among animal species, which may be related to
the duration of high cholesterol intake. Currently, serum
parameters of N-HDL, LDL/HDL and HDL/LDL have
been clinically used for predicting the risk of CVD in pa-
tients with dyslipidemia, as well as monitoring the effect-
iveness of lipid-lowering agent in patients [29–31]. As
observed in the present study, HCBD-fed mice showed a
Table 3 Effects of FSC-S and FSC-SpEt supplementation on hepatic size and liver function in normal and experimental hypercholes-
terolemic (HCL) mice
Groups Drug dose (%, w/w) Hepatic weight (g) Hepatic index Serum ALTactivity (U/L)
Normal mice
ND – 1.69 ± 0.06 5.98 ± 0.13 53.70 ± 4.30
ND/FSC-S 9 1.90 ± 0.13 9.32 ± 0.39** 42.83 ± 3.06
ND/FSC-SpEt 9 1.85 ± 0.04* 6.55 ± 0.08** 42.58 ± 3.75
ND/FF 0.05 2.75 ± 0.05** 10.00 ± 0.11** 46.59 ± 4.98
HCL mice
ND – 1.79 ± 0.06 6.11 ± 0.07 50.88 ± 1.30
HCBD – 2.07 ± 0.05** 7.12 ± 0.09** 62.00 ± 3.59*
HCBD/FSC-S 3 2.56 ± 0.14## 8.81 ± 0.47## 73.78 ± 6.45
9 2.87 ± 0.17## 11.28 ± 0.51## 82.63 ± 6.11#
HCBD/FSC-SpEt 3 1.99 ± 0.18 6.95 ± 0.15 71.50 ± 2.99
9 2.01 ± 0.11 7.37 ± 0.13 63.25 ± 2.55
HCBD/FF 0.05 3.46 ± 0.08## 12.19 ± 0.20## 110.50 ± 13.06##
Experimental details were described in Table 1. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Ten days after
supplemetnation, hepatic weight and index, as well as serum alanine aminotransferase (ALT) activity were measured. Hepatic index was estimated from the ratio
of its weight to body weight × 100. Values given are the means ± SEM, with n = 10. *P < 0.05, **P < 0.01 vs ND; #P < 0.05, ##P < 0.01 vs HCBD. Statistical significant
differences were determined using a one-way ANOVA followed by Dunnett’s multiple comparisons test or post-hoc analysis
Chu et al. Lipids in Health and Disease  (2015) 14:93 Page 4 of 12
Table 4 Effects of FSC-S and FSC-SpEt supplementation on organ/tissue mass in normal and experimental hypercholesterolemic (HCL) mice
Groups Drug dose
(%, w/w)
Weight (g) Index 1 Index 2
Fat Kindey Spleen Testis Fat Kindey Spleen Testis Fat Kindey Spleen Testis
Normal mice
ND – 0.25 ± 0.02 0.45 ± 0.02 0.14 ± 0.01 0.17 ± 0.01 0.90 ± 0.06 1.59 ± 0.06 0.51 ± 0.03 0.59 ± 0.04 0.96 ± 0.06 1.69 ± 0.06 0.54 ± 0.03 0.62 ± 0.04
ND/FSC-S 9 0.04 ± 0.01** 0.25 ± 0.01** 0.07 ± 0.01** 0.16 ± 0.01 0.19 ± 0.02** 1.22 ± 0.03** 0.36 ± 0.02** 0.78 ± 0.04** 0.21 ± 0.02** 1.35 ± 0.04** 0.39 ± 0.02** 0.86 ± 0.04**
ND/FSC-SpEt 9 0.24 ± 0.01 0.47 ± 0.01 0.13 ± 0.01 0.19 ± 0.01 0.83 ± 0.04 1.67 ± 0.03 0.45 ± 0.01 0.66 ± 0.02 0.89 ± 0.04 1.79 ± 0.03 0.49 ± 0.02 0.70 ± 0.02
ND/FF 0.05 0.12 ± 0.01** 0.44 ± 0.02 0.12 ± 0.01* 0.18 ± 0.01 0.45 ± 0.05** 1.59 ± 0.04 0.45 ± 0.02 0.66 ± 0.03 0.50 ± 0.05** 1.76 ± 0.05 0.50 ± 0.03 0.74 ± 0.03*
HCL mice
ND – 0.32 ± 0.02 0.48 ± 0.02 0.15 ± 0.01 0.20 ± 0.01 1.10 ± 0.05 1.65 ± 0.43 0.50 ± 0.02 0.69 ± 0.03 1.17 ± 0.05 1.76 ± 0.05 0.53 ± 0.02 0.74 ± 0.03
HCBD – 0.23 ± 0.02** 0.48 ± 0.01 0.14 ± 0.01 0.20 ± 0.01 0.79 ± 0.06** 1.64 ± 0.04 0.50 ± 0.03 0.69 ± 0.03 0.85 ± 0.07** 1.77 ± 0.04 0.53 ± 0.03 0.74 ± 0.04
HCBD/FSC-S 3 0.26 ± 0.02 0.46 ± 0.02 0.15 ± 0.01 0.20 ± 0.01 0.88 ± 0.07 1.58 ± 0.05 0.51 ± 0.04 0.68 ± 0.02 0.97 ± 0.08 1.73 ± 0.05 0.56 ± 0.42 0.75 ± 0.02
9 0.13 ± 0.02## 0.35 ± 0.01## 0.11 ± 0.01## 0.18 ± 0.01 0.49 ± 0.07## 1.39 ± 0.03## 0.44 ± 0.02 0.71 ± 0.04 0.56 ± 0.08# 1.57 ± 0.03## 0.49 ± 0.03 0.80 ± 0.05
HCBD/FSC-SpEt 3 0.21 ± 0.02 0.48 ± 0.02 0.14 ± 0.01 0.19 ± 0.01 0.71 ± 0.06 1.68 ± 0.06 0.50 ± 0.02 0.67 ± 0.03 0.77 ± 0.06 1.81 ± 0.07 0.53 ± 0.02 0.72 ± 0.04
9 0.20 ± 0.02 0.48 ± 0.02 0.12 ± 0.01 0.20 ± 0.01 0.70 ± 0.06 1.70 ± 0.04 0.43 ± 0.02 0.70 ± 0.03 0.76 ± 0.07 1.84 ± 0.05 0.46 ± 0.03 0.75 ± 0.04
HCBD/FF 0.05 0.13 ± 0.01## 0.51 ± 0.20 0.12 ± 0.01# 0.20 ± 0.01 0.45 ± 0.02## 1.79 ± 0.07 0.41 ± 0.03# 0.71 ± 0.02 0.51 ± 0.02## 2.03 ± 0.08## 0.47 ± 0.03 0.80 ± 0.02
Experimental details were described in Table 1. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Ten days after supplementation, epididymis fat, kidney, spleen and testis mass
and index were measured. Index 1 and index 2 were estimated from the ratio of their weight to body weight × 100 or their weight to body weight – liver weight × 100, respectively. Values given are the means ± SEM,
















decrease in serum HDL/LDL and increases in serum N-
HDL and LDL/HDL values. This animal model may be
appropriately used for evaluating the effectiveness of drug
on serum lipid profile, which is predictive of risk on CVD.
FSC-S supplementation was found to increase serum lipid
levels, including those of “good cholesterol” and “bad
cholesterol”, in both normal and HCL mice. While
FSC-SpEt increased serum HDL level and HDL/LDL
ratio, it decreased serum TG, LDL, and N-HDL levels.
Currently, it is widely believed that bad cholesterol
plays an important role in the development of CVD. In
contrast, good cholesterol is responsible for returning
Table 5 Effects of FSC-S and FSC-SpEt supplementation on stomach and residual gastric content and fecal TC excretion in normal
and experimental hypercholesterolemic (HCL) mice
Groups Drug dose
(%, w/w)
Stomach Residual gastric content Fecal
TC (μmol/g)Weight (g) Index 1 Index 2 Weight (g) Index 1 Index 2
Normal mice
ND – 0.34 ± 0.02 1.18 ± 0.06 1.26 ± 0.06 0.55 ± 0.06 1.92 ± 0.20 2.05 ± 0.21 5.91 ± 0.22
ND/FSC-S 9 0.25 ± 0.02** 1.25 ± 0.06 1.38 ± 0.07 0.73 ± 0.06* 3.59 ± 0.20** 3.97 ± 0.23** 5.21 ± 0.57
ND/FSC-SpEt 9 0.32 ± 0.01 1.12 ± 0.03 1.20 ± 0.03 0.45 ± 0.05 1.59 ± 0.19 1.70 ± 0.20 4.82 ± 0.29**
ND/FF 0.05 0.28 ± 0.02* 1.02 ± 0.05* 1.31 ± 0.06 0.42 ± 0.03 1.53 ± 0.10 1.70 ± 0.11 6.72 ± 0.40
HCL mice
ND – 0.31 ± 0.01 1.06 ± 0.03 1.13 ± 0.03 0.61 ± 0.09 2.06 ± 0.26 2.20 ± 0.28 5.24 ± 0.47
HCBD – 0.30 ± 0.01 1.05 ± 0.03 1.12 ± 0.03 0.53 ± 0.06 1.82 ± 0.20 1.96 ± 0.22 23.18 ± 1.00**
HCBD/FSC-S 3 0.29 ± 0.01 0.99 ± 0.04 1.08 ± 0.04 0.49 ± 0.09 1.70 ± 0.32 1.88 ± 0.37 23.72 ± 0.80
9 0.28 ± 0.01 1.12 ± 0.04 1.26 ± 0.04# 0.66 ± 0.08 2.57 ± 0.27# 2.91 ± 0.31# 20.86 ± 1.06
HCBD/FSC-SpEt 3 0.31 ± 0.02 1.08 ± 0.06 1.16 ± 0.06 0.36 ± 0.02# 1.27 ± 0.07# 1.37 ± 0.08# 25.43 ± 1.72
9 0.30 ± 0.01 1.07 ± 0.04 1.15 ± 0.04 0.41 ± 0.04# 1.41 ± 0.12 1.53 ± 0.13 24.87 ± 0.96
HCBD/FF 0.05 0.31 ± 0.01 1.10 ± 0.04 1.25 ± 0.04# 0.37 ± 0.04# 1.29 ± 0.11# 1.47 ± 0.12 27.84 ± 1.19##
Experimental details were described in Table 1 and 3. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Ten days after
supplementation, stomach weight and the values of gastric content and fecal TC were measured. Stomach and residual gastric content index was estimated from
the ratio of their weight to body weight × 100 (index 1) or the ratio of their weight to body weight – liver weight × 100 (index 2). Values given are the means ±
SEM, with n = 10. *P < 0.05, **P < 0.01 vs ND; #P < 0.05, ##P < 0.01 vs HCBD. Statistical significant differences were determined using a one-way ANOVA followed by
Dunnett’s multiple comparisons test or post-hoc analysis




BW (g) BW gain (g) BW (g) at BW-LW (g)
at D10at D0 D2-D0 D6-D0 D10-D0 D10
Normal mice
ND – 17.10 ± 0.23 3.99 ± 0.76 8.13 ± 0.49 11.17 ± 0.54 28.27 ± 0.47 26.57 ± 0.43
ND/FSC-S 9 17.41 ± 0.22 -0.92 ± 0.41** 0.71 ± 0.56** 2.80 ± 0.86** 20.22 ± 0.73** 18.32 ± 0.62**
ND/FSC-SpEt 9 17.21 ± 0.21 3.87 ± 0.30 8.33 ± 0.41 11.05 ± 0.34 28.26 ± 0.26 26.41 ± 0.23
ND/FF 0.05 17.33 ± 0.23 3.82 ± 0.46 7.33 ± 0.59 10.21 ± 0.69 27.54 ± 0.55 24.79 ± 0.51*
HCL mice
ND – 20.74 ± 0.40 2.73 ± 0.52 5.90 ± 0.70 8.45 ± 0.71 29.19 ± 0.68 27.40 ± 062
HCBD – 20.73 ± 0.28 2.41 ± 0.45 5.88 ± 0.39 8.25 ± 0.49 28.99 ± 0.47 26.92 ± 0.48
HCBD/FSC-S 3 20.52 ± 0..31 2.87 ± 0.55 6.45 ± 0.70 8.57 ± 0.64 29.09 ± 0.68 26.53 ± 0.63
9 20.90 ± 0.37 -0.78 ± 0.41## 2.06 ± 0.60## 4.41 ± 0.79## 25.31 ± 0.61## 22.44 ± 0.49##
HCBD/FSC-SpEt 3 20.29 ± 0.35 2.87 ± 0.38 6.31 ± 0.48 8.37 ± 0.69 28.66 ± 0.54 26.66 ± 0.50
9 20.71 ± 0.34 2.61 ± 0.40 5.53 ± 0.85 7.71 ± 0.72 28.42 ± 0.79 26.32 ± 0.70
HCBD/FF 0.05 20.67 ± 0.35 3.29 ± 0.39 6.31 ± 0.41 7.74 ± 0.54 28.40 ± 0.46 24.94 ± 0.40##
Experimental details were described in Table 1. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation. Body weight (BW) in
each mouse was measured before medication (D0) and at D2, D6 and D10 following administration of drug. In addition, the values of BW minus liver weight (LW)
were also determined due to hepatomegaly caused by FSC-S and FF supplement. Values given are the means ± SEM, with n = 10. *P < 0.05, **P < 0.01 vs ND;
#P < 0.05, ##P < 0.01 vs HCBD. Statistical significant differences were determined using a one-way ANOVA followed by Dunnett’s multiple comparisons test or
post-hoc analysis
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excessive cholesterol in the bloodstream back to the
liver where it is excreted in bile. Given the beneficial ef-
fect of FSC-SpEt on serum lipid profile, it may be po-
tentially used for alternative treatment in patients with
hyperlipidemia.
The liver plays a key role in lipid metabolism. Feeding
mice with HCBD for 10 days increased hepatic lipid ac-
cumulation and size, which was associated with liver in-
jury, as evidenced by an increase in serum ALT activity.
Although both FSC-S and FSC-SpEt supplementations
did not reduce hepatic lipid content in HCL mice, they
lowered hepatic TC contents in normal mice. FSC-S
supplementation also decreased hepatic GLU content in
both normal and HCL mice. The ability of FSC-S and
FSC-SpEt supplementation to elevate serum TC levels
and lower hepatic TC content may be related to the re-
lease of hepatic TC into bloodstream in supplemented
mice. Given that lignans presented in FSC could im-
prove insulin sensitivity via activating the peroxisome
proliferator-activated receptor (PPAR)-γ pathways [15].
The supplementation with FSC-S, but not FSC-SpEt
(which is deprived of lignans), reduced serum and hep-
atic GLU levels in mice. It has been demonstrated that
FSC has hepatoprotective activity [13]. However, serum
ALT activity was slightly elevated in the FSC-S-
supplemented HCL mice. This observation may be re-
lated to the increase in liver size in HCL mice.
While FSC-S supplementation decreased body weight,
epididymis fat, kidney and spleen weight and indices in
normal and HCL mice, FSC-SpEt only induced an
increase in liver size in normal mice. The observation
that losses of body weight and fat occurred in FSC-S
supplemented mice suggests the utilization of FSC-S as
a prophylactic or therapeutic agent in overweight or
obese individuals. Although the amount of food intake
and the ratio of food intake to metabolic body mass as
indicated by RFBW were reduced in both FSC-S/normal
and FSC-S/HCL mice, their FEI values markedly in-
creased as compared with the corresponding un-
supplemented animals. This indicated that some
ingested food/energy is not converted into body mass in
both normal and HCL mice supplemented with FSC-S.
FEI (weight gain per unit of food ingested) is an index
reflecting the amount of feed to produce one kilogram
of meat in animal husbandry industry [32–36]. In this
study, FEI reflects the FSC-S-induced body weight loss
in normal and HCL mice.
FF, a synthetic fibric acid derivative, is a prescribed
drug for the treatment of dyslipidemia. The therapeutic
effect of FF, which is mediated by PPAR-α activation, is
consisted of reduction in the blood TC and LDL, espe-
cially TG levels, as well as the associated increase in
HDL [37, 38]. In the present study, FF supplementation
decreased serum TC, TG, LDL and N-HDL levels, but it
increased HDL/LDL in HCL mice. In addition, FF also
lowered hepatic TC, TG and GLU levels in both normal
and HCL mice. Despite the fact that FF produces a sig-
nificant effect on the metabolism of lipids as well as
GLU, including down-regulation of lipogenesis and up-
regulation of fatty acid oxidation [39], the liver injury, as
Table 7 Effects of FSC-S and FSC-SpEt supplementation on food, water and drug intake in normal and experimental hypercholester-
olemic (HCL) mice
Groups Drug dose (%, w/w) Food intake (g/kg/day) RFBW FEI Water intake (ml/kg/day) RWBW WEI Drug intake (g/kg/day)
Normal mice
ND – 176.74 1.56 3.95 310.90 2.94 7.44 –
ND/FSC-S 9 130.09 1.28 9.21 222.57 2.01 14.50 12.73
ND/FSC-SpEt 9 169.48 1.66 4.24 276.40 1.06 6.29 16.76
ND/FF 0.05 167.29 1.49 4.03 287.38 2.56 6.92 0.08
HCL mice
ND – 184.89 1.67 5.78 269.88 2.44 8.44 –
HCBD – 174.75 1.57 5.53 271.64 2.47 8.68 –
HCBD/FSC-S 3 165.93 1.57 5.33 257.95 2.37 8.04 5.13
9 129.31 1.28 7.36 236.87 2.14 12.27 12.79
HCBD/FSC-SpEt 3 176.02 1.67 5.72 271.91 2.50 8.57 5.44
9 181.26 1.83 6.75 244.30 2.24 8.28 17.93
HCBD/FF 0.05 192.56 1.81 6.63 265.16 2.49 9.13 0.10
Experimental details were described in Table 1. Mice were fed with ND and HCBD without or with FSC-S, FSC-SpEt, or FF supplementation for 10 days. During
supplementation, the volumes of food/water/drug intake and the ratio of food/water intake to body weight were estimated in each group. The dosages of drug
intake (g/kg/day) were determined by noting the amount of ingested diet (g/kg/day) and the drug concentrations in the diet. The weight of drug was subtracted
from the food intake. FSC-S and FSC-SpEt doses were based on their crude herbal material. The ratio of food (g) and water (mL) intake to body weight (g) (RFBW
and RWBW, respectively) was calculated by using the formula as follow: total food (g) and water (mL) intake divided total body weight (g) for an experimental
period of 10 days. The feed efficiency index (FEI) and water efficiency index (WEI) was calculated by using the formula as follow: food (g) and water (mL)
consumption divided body weight gain (g) for the 10 days of treatment with drugs
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indicated by high serum ALT activity and hepatomegaly,
was aggravated by FF treatment in HCL mice. This is
consistent with the earlier experimental and clinical ob-
servations [20, 21, 40–42].
Chinese herbal medicine (CHM) has been used for over
2000 years in China. Since the introduction of Western
medicine in China during the 16th century, CHM has be-
come an alternative medicine rather than the mainstream
medicine in China [43]. In recent decades, however, more
and more people suffer from chronic diseases which can-
not be treated effectively with chemical drugs in Western
medicine. Consequently, complementary and alternative
medicine, including CHM, has gained more attention and
thus becomes popular [44, 9]. Today, about 80 % of people
worldwide rely on herbal medicines for some aspects of
their primary health care, and more than 8000 varieties of
CHM or related herbal products are now exported from
China to more than 130 countries and regions [44, 11].
The increasing demand for herbal products in the global
market would likely pose tremendous challenge on herbal
resources in the world. For example, the Panax herb (eg.
ginseng) was being consumed by millions and millions of
people around the world, while wild Panax japonicus
plants have become increasingly rare in China [45]. The
effects of crude FSC-S (without any processing) and FSC-
SpEt (usually treated as waste in the modern pharmaceut-
ical industry) were compared in normal and HCL mice in
the present study which aimed to demonstrate how nat-
ural herbal material can be fully utilized. The research
and development of herbal medicine, while under the
guidance of scientific principle, should be economical,
simple, safe, effective, and environmental friendly. Re-
sults obtained from the present study showed that both
crude herb FSC-S and its “waste” FSC-SpEt possess a
variety of bioactivities resembling its “active extract” or
“active compound”.
In conclusion, results obtained from the present study
suggested that daily supplementation with FSC-S and
FSC-SpEt may provide an effective alternative interven-
tion for the management of hyperlipidemia/fatty liver
and overweight/obesity, respectively. Data are summa-
rized in Table 8.
Table 8 A summary on the effects of FSC-S and FSC-SpEt supplementation in normal and experimental hypercholesterolemic (HCL)
mice
FSC-S FSC-SpEt FF FSC-S FSC-SpEt FF
9 % 9 % 3 % 9 % 3 % 9 %
Vs normal mice Vs HCL mice
Serum TC ↑ ↑ — Serum TC ↑ ↑ — — ↓
TG ↑ — ↓ TG — ↑ ↓ ↓ ↓
HDL ↑ — — HDL ↑ ↑ — ↑ ↓
LDL ↑ ↑ — LDL ↑ ↑ — — ↓
ALT activity — — — ALT activity — ↑ — — ↑
LDL/HDL — ↑ — LDL/HDL ↑ — — ↓ ↓
HDL/LDL — ↓ — HDL/LDL ↓ — — ↑ ↑
N-HDL ↑ ↑ — N-HDL — ↑ — ↓ ↓
Hepatic TC ↓ ↓ ↓ Hepatic TC — — — — ↓
TG ↑ ↓ ↓ TG — ↑ — — ↓
Glucose ↓ — ↓ Glucose ↓ ↓ — — ↓
Body weight ↓ — — Body weight — ↓ — — —
BW - liver weight ↓ — ↓ BW - liver weight — ↓ — — ↓
Liver index/weight —/↑ ↑/↑ ↑/↑ Liver index/weight ↑/↑ ↑/↑ —/— —/— ↑/↑
Fat index/weight ↓/↓ —/— ↓/↓ Fat index/weight —/— ↓/↓ —/— —/— ↓/↓
Kidney index/weight ↓/↓ —/— —/— Kidney index/weight —/— ↓/↓ —/— —/— ↑/—
Spleen index/weight ↓/↓ —/— —/↓ Spleen index/weight —/— —/↓ —/— —/— ↓/↓
Testis index/weight ↑/— —/— —/— Testis index/weight —/— —/— —/— —/— —/—
Stomach index/weight —/↓ —/— ↓/↓ Stomach index/weight —/— ↑/— —/— —/— ↑/—
Gas-content index/weight ↑/↑ —/— —/— Gas-content index/weight —/— ↑/— ↓/↓ —/↓ ↓/↓
Fecal TC — ↓ — Fecal TC — — — — ↑
↑: increased or elevated; ↓: decreased or inhibited; —: unaltered
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Materials and methods
Preparation of FSC-S and FSC-SpEt
FSC was purchased from Guangzhou ZhiXin herbal Co.,
Ltd and authenticated by Professor Chun-Sheng Liu at
Beijing University of Chinese Medicine. FSC were manu-
ally peeled off and its seeds were washed with distilled
water for removing the residual pulps. For the prepar-
ation of post-ethanol extraction FSC seeds, the dried
seeds were crushed into small pieces using an industrial
grinder and extracted twice (first, 1.5 h; second, 2 h)
with 5 volumes of 80 % (v/v, in H2O) ethanol under re-
flux after soaking for half an hour. FSC-SpEt was dried
at room temperature. Both FSC-S and FSC-SpEt were
smashed to pass through the 60 mesh sieve and stored
at 4 °C until use.
Chemicals and regents
FF (certificate number 20667) was bought from Beijing
Jinxiang Medical Ltd (Beijing, People’s Republic of
China). Cholesterol (certificate number 20120614) and
bile salt (certificate number 20121210) were purchased
from Beijing Chemical Reagent Co (Beijing, People’s Re-
public of China). Assay kits for TC (certificate number
141721), TG (certificate number 146781), and GLU (cer-
tificate number 143291) were supplied by Zhongsheng
Beikong Biotechnology and Science Inc. (Beijing, Peo-
ple’s Republic of China). Assay kits for HDL, LDL and
ALT were bought from Zhongsheng Beikong Bio-
technology and Science Inc. (Beijing, People’s Republic
of China) or Beijing Leadman Biochemistry Co Ltd
(Beijing, People’s Republic of China).
Animal and treatment
Male ICR (grade II, certificate number SCXK [jing]
2012-0001) mice weighing 17—21 g were obtained from
Vital River Lab Animal Co Ltd (Beijing, People’s Repub-
lic of China). Animals were housed under controlled
conditions (20 °C—22 °C, relative humidity 50—55 %,
12:12-h dark-light cycle) with free access to regular chow
and water. Blood and liver samples were obtained from
Fig. 1 Experimental design of studies on FSC-S and FSC-SpEt in normal and HCL mice. Abbreviations: FSC-S: Fructus Schisandrae Chinensis seed;
FSC-SpEt: post-ethanol extraction residue of FSC-S; TC: total cholesterol; TG: triglyceride; LDL: low-density lipoprotein; HDL: high-density lipoprotein;
N-HDL: non-HDL; ALT: alanine aminotransferase; HCL: hypercholesterolemia
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ether-anesthetized animals that had been fasted for 6 h
(from 6 am to 12 noon) and were subjected to biochem-
ical analysis. All experimental procedures were approved
by the University Committee on Research Practice at the
Beijing University of Chinese Medicine.
Experimental design
Design 1
In this study, the effects of FSC-S and FSC-SpEt supple-
mentation on lipids, GLU, and liver function were in-
vestigated in normal mice. Animals were divided into
four groups of 10 animals in each: Group 1, mice fed
with ND; Group 2, 3, 4, mice fed with ND supple-
mented with 9 % FSC-S, 9 % FSC-SpEt, and 0.05 % FF
(w/w), respectively. After 10 days of supplementation,
mice were sacrificed under light ether anesthesia. Blood
samples were collected from the orbital vein, and liver
tissue samples were obtained and subjected to bio-
chemical analysis.
Design 2
This study was designed to investigate the effects of
FSC-S and FSC-SpEt supplementation on serum and
hepatic parameters in HCL mice. Animals were ran-
domly divided into four groups of 10 animals in each:
Group 1, mice fed with ND; Group 2, mice fed with high
cholesterol/bile salt (1/0.3 %, w/w) diet (HCBD); Group
3, 4, 5, and 6, mice fed with HCBD supplemented with
FSC-S (3 %, 9 %) and FSC-SpEt (3 %, 9 %), respectively;
Group 7, mice fed with HCBD supplemented with 0.05 %
FF. After 10 days of supplementation, mice were sacrificed
under light ether anesthesia. Blood samples were collected
from the orbital vein, and liver tissue samples were ob-
tained and subjected to biochemical analysis. Figure 1
shows the design of this study.
Preparation of serum and hepatic supernatant fractions
Blood samples were collected from the orbital vein and
centrifuged at 3000 × g for 8 min, and stored at −80 °C
until used for biochemical analysis. Liver tissue samples
were homogenized in 9 volumes of 0.9 % (w/v) NaCl so-
lution by two 10 s bursts of a tissue disintegrator at
13,500 rpm and then stored at −20 °C until analysis
within 48 h. The liver homogenates were centrifuged at
3500 × g for 15 min to obtain the supernatant fraction
for lipid determination.
Biochemical analysis
Ten μL serum and 30 μL hepatic supernatant were used
to assay for TG and TC levels with glycerol phosphate
oxidase-p-aminophenazone (GPO-PAP) and cholesterol
oxidase phenol 4-aminoantipyrine peroxidase (COD-
PAP) methods, respectively. Ten μL serum and hepatic
supernatant were used to determine the GLU levels with
GLU oxidase-peroxidase (GOD-POD) method. Mouse
feces were collected on D10 and dried at room
temperature. The dried feces (approximately 30 mg) were
smashed and extracted with 0.5 mL chloroform-methanol
(1:1, v/v) mixture for 12 h and then centrifuged at 2000 ×
g for 5 min to obtain the supernatants. Aliquots (30 μL) of
fecal supernatants were used to measure the TC levels
by using the COD-PAP method. All methods were per-
formed according to the manufacturer's instructions.
An automatic biochemistry analyzer (Synchron CX4 PRO;
Beckman Coulter, Brea, CA, USA) was used to automatic-
ally measure the serum HDL and LDL levels and the ALT
activity by a colorimetric method. In addition, serum non-
HDL (N-HDL) levels were calculated as: TC – HDL.
Measurement of body weight and organ indices
Body weight was measured every two days. At D10, the
liver, epididymal fat, spleen, kidney, testis, and stomach,
as well as residual gastric content were weighed. Organ/
residual gastric content index 1 was calculated as organ
weight or residual gastric content/body weight × 100.
Organ/residual gastric content index 2 was calculated as
[organ or residual gastric content/(body weight – liver
weight)] × 100.
Measurement of RFBW, RWBW, FEI, and WEI
RFBW and RWBW were calculated by using the formula
as follow: total food (g) or water (mL) intake was divided
by the total body weight (g) within the 10-day supplemen-
tation period. FEI and WEI were calculated by using the
formula as follow: food (g) or water (mL) consumption di-
vided by the body weight gain (g) for the duration of
10 days of supplementation with FSC-S, FSC-SpEt, or FF.
Statistical analysis
The results are presented as the means ± SEM. Data
were analyzed by one-way ANOVA. Comparisons be-
tween two groups were performed using the Dunnett’s
multiple comparisons test or post-hoc analysis. Differ-
ences were considered significant at P < 0.05. Statistical
tests of data were performed using the SPSS 20.0 statis-
tical analysis program.
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